메뉴 건너뛰기
Journal of Cancer Research and Clinical Oncology
Volumn 140, Issue 2, 2014, Pages 221-226
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients
Author keywords

Advanced breast cancer; Capecitabine; Diarrhea; HER2 positive; Lapatinib; Schedule modification
Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; SURVIVAL RATE;
EID: 84895074975     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1556-4     Document Type: Article
Times cited : (8)
References (20)
  • 1
    • 0035970795 scopus 로고    scopus 로고
    • Sample size tables for exact single-stage phase II designs
    • 11252008 10.1002/sim.721
    • A'Hern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20:859-866
    • (2001) Stat Med , vol.20 , pp. 859-866
    • A'Hern, R.P.1
  • 2
    • 84857236823 scopus 로고    scopus 로고
    • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
    • 1:CAS:528:DC%2BC38XisFWjsrs%3D 22257673 10.1016/S0140-6736(11)61847-3
    • Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640
    • (2012) Lancet , vol.379 , pp. 633-640
    • Baselga, J.1    Bradbury, I.2    Eidtmann, H.3
  • 3
    • 4344708355 scopus 로고    scopus 로고
    • Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    • 1:CAS:528:DC%2BD2cXpsVWktbs%3D 15254061 10.1200/JCO.2004.04.132
    • Benson AB 3rd, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918-2926
    • (2004) J Clin Oncol , vol.22 , pp. 2918-2926
    • Benson III, A.B.1    Ajani, J.A.2    Catalano, R.B.3
  • 4
    • 61649118623 scopus 로고    scopus 로고
    • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
    • 1:STN:280:DC%2BD1MzmtlGltQ%3D%3D 19179558 10.1093/annonc/mdn759
    • Blackwell KL, Pegram MD, Tan-Chiu E et al (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026-1031
    • (2009) Ann Oncol , vol.20 , pp. 1026-1031
    • Blackwell, K.L.1    Pegram, M.D.2    Tan-Chiu, E.3
  • 5
    • 44849108294 scopus 로고    scopus 로고
    • A phase II study of lapatinib monotherapy in chemotherapy refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
    • 1:STN:280:DC%2BD1czktlSgsA%3D%3D 18283035 10.1093/annonc/mdm601
    • Burstein HJ, Storniolo AM, Franco S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068-1074
    • (2008) Ann Oncol , vol.19 , pp. 1068-1074
    • Burstein, H.J.1    Storniolo, A.M.2    Franco, S.3
  • 6
    • 77957771125 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial
    • 1:CAS:528:DC%2BC3cXhtlWjsbrP
    • Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncol 15:924-934
    • (2010) Oncol , vol.15 , pp. 924-934
    • Cameron, D.1    Casey, M.2    Oliva, C.3    Newstat, B.4    Imwalle, B.5    Geyer, C.E.6
  • 7
    • 77949540771 scopus 로고    scopus 로고
    • An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
    • 1:STN:280:DC%2BC3c7isVKqsQ%3D%3D 19815649 10.1093/annonc/mdp373
    • Capri G, Chang J, Chen SC et al (2010) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21:474-480
    • (2010) Ann Oncol , vol.21 , pp. 474-480
    • Capri, G.1    Chang, J.2    Chen, S.C.3
  • 8
    • 53949101266 scopus 로고    scopus 로고
    • Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
    • 1:CAS:528:DC%2BD1cXht1Cms73P 18204897 10.1007/s10549-007-9860-9
    • Crown JP, Burris HA 3rd, Boyle F et al (2008) Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112:317-325
    • (2008) Breast Cancer Res Treat , vol.112 , pp. 317-325
    • Crown, J.P.1    Burris III, H.A.2    Boyle, F.3
  • 9
    • 73949090721 scopus 로고    scopus 로고
    • Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
    • 1:CAS:528:DC%2BC3cXhtF2rsr0%3D 19933921 10.1200/JCO.2008.19.9844
    • Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92-98
    • (2010) J Clin Oncol , vol.28 , pp. 92-98
    • Dawood, S.1    Broglio, K.2    Buzdar, A.U.3    Hortobagyi, G.N.4    Giordano, S.H.5
  • 10
    • 84856227263 scopus 로고    scopus 로고
    • Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    • 1:CAS:528:DC%2BC3MXhs1ajt73M 21898114 10.1007/s10549-011-1749-y
    • Gajria D, Gonzalez J, Feigin K et al (2012) Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 131:111-116
    • (2012) Breast Cancer Res Treat , vol.131 , pp. 111-116
    • Gajria, D.1    Gonzalez, J.2    Feigin, K.3
  • 11
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538 10.1056/NEJMoa064320
    • Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 12
    • 46449113024 scopus 로고    scopus 로고
    • Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
    • 1:CAS:528:DC%2BD1cXoslOqsLo%3D 18458039 10.1200/JCO.2007.14.0590
    • Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005
    • (2008) J Clin Oncol , vol.26 , pp. 2999-3005
    • Gomez, H.L.1    Doval, D.C.2    Chavez, M.A.3
  • 13
    • 84871712684 scopus 로고    scopus 로고
    • Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial
    • 1:CAS:528:DC%2BC3sXhsV2ltw%3D%3D 23234763 10.1016/S1470-2045(12)70508-9
    • Goss PE, Smith IE, O'Shaughnessy J et al (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14:88-96
    • (2013) Lancet Oncol , vol.14 , pp. 88-96
    • Goss, P.E.1    Smith, I.E.2    O'Shaughnessy, J.3
  • 14
    • 84864018421 scopus 로고    scopus 로고
    • Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study
    • 1:CAS:528:DC%2BC38XpvVSgtrs%3D 22493419 10.1200/JCO.2011.39.0823
    • Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989-1995
    • (2012) J Clin Oncol , vol.30 , pp. 1989-1995
    • Guarneri, V.1    Frassoldati, A.2    Bottini, A.3
  • 15
    • 34249944752 scopus 로고    scopus 로고
    • Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer
    • abstr 1091
    • Iwata H, Toi M, Fujiwara Y et al (2006) Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 100(suppl; abstr 1091):S68
    • (2006) Breast Cancer Res Treat , vol.100 , Issue.SUPPL.
    • Iwata, H.1    Toi, M.2    Fujiwara, Y.3
  • 16
    • 34548222618 scopus 로고    scopus 로고
    • Lapatinib-associated toxicity and practical management recommendations
    • 1:CAS:528:DC%2BD2sXpslertbs%3D 17673607 10.1634/theoncologist.12-7-756
    • Moy B, Goss PE (2007) Lapatinib-associated toxicity and practical management recommendations. Oncologist 12:756-765
    • (2007) Oncologist , vol.12 , pp. 756-765
    • Moy, B.1    Goss, P.E.2
  • 17
    • 66249091930 scopus 로고    scopus 로고
    • The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine
    • 1:CAS:528:DC%2BD1MXlvFOhtLw%3D 19346299 10.1634/theoncologist.2008-0230
    • Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368
    • (2009) Oncologist , vol.14 , pp. 320-368
    • Ross, J.S.1    Slodkowska, E.A.2    Symmans, W.F.3    Pusztai, L.4    Ravdin, P.M.5    Hortobagyi, G.N.6
  • 18
    • 33644935686 scopus 로고    scopus 로고
    • Phase i study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
    • 1402306 16504126 10.1186/1471-2407-6-42
    • Santini D, Vincenzi B, Schiavon G et al (2006) Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC Cancer 6:42
    • (2006) BMC Cancer , vol.6 , pp. 42
    • Santini, D.1    Vincenzi, B.2    Schiavon, G.3
  • 19
    • 84856444501 scopus 로고    scopus 로고
    • Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial
    • 1:CAS:528:DC%2BC38XitVSmurc%3D 22257523 10.1016/S1470-2045(11)70397-7
    • Untch M, Loibl S, Bischoff J et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135-144
    • (2012) Lancet Oncol , vol.13 , pp. 135-144
    • Untch, M.1    Loibl, S.2    Bischoff, J.3
  • 20
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • 1:CAS:528:DC%2BC38Xhs1ekt73M 23020162 10.1056/NEJMoa1209124
    • Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.